Windtree Therapeutics ( (WINT) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Windtree Therapeutics, Inc. has announced a delay in the filing of its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for this delay is the need for additional time to finalize the company’s financial statements and related disclosures, which could not be completed without unreasonable effort or expense. The company anticipates filing the report within five calendar days following the prescribed due date. Windtree Therapeutics does not expect any significant changes in its financial results compared to the same period last year. The notification was signed by Jed Latkin, the President and CEO, who assured ongoing compliance efforts.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Average Trading Volume: 11,148,026
Technical Sentiment Signal: Sell
Current Market Cap: $14.85M
For a thorough assessment of WINT stock, go to TipRanks’ Stock Analysis page.